Petmed Express (NASDAQ:PETS) Releases Earnings Results, Beats Expectations By $0.07 EPS

Petmed Express (NASDAQ:PETS) issued its quarterly earnings results on Monday. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.07, Briefing.com reports. Petmed Express had a return on equity of 23.42% and a net margin of 11.05%. The company had revenue of $69.94 million for the quarter, compared to analyst estimates of $69.65 million. During the same period in the previous year, the company posted $0.52 earnings per share. The company’s quarterly revenue was down 2.0% compared to the same quarter last year.

NASDAQ:PETS opened at $26.00 on Tuesday. Petmed Express has a 12-month low of $15.00 and a 12-month high of $33.28. The stock’s 50 day moving average price is $17.97 and its two-hundred day moving average price is $18.06. The firm has a market capitalization of $392.20 million, a price-to-earnings ratio of 13.14 and a beta of 0.57.

PETS has been the topic of several research analyst reports. Craig Hallum upped their price objective on Petmed Express from $15.00 to $20.00 and gave the company a “hold” rating in a research note on Thursday, October 17th. ValuEngine upgraded Petmed Express from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, BidaskClub upgraded Petmed Express from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

About Petmed Express

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Featured Article: Convertible Shares

Earnings History for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.